Category Archives: Cell Therapy

Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer.

Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published detailed results of aPhase I/II trial evaluating its lead candidate ilixadencel, which is currently in Phase II to treat metastatic renal cell carcinoma (mRCC),for which no effective treatments are available.

The experimental therapy was administered in combination with Pfizers sunitinib, approved for the treatment of RCC, and Immunicum has kept monitoring the 11 patients after officially completing the study in 2014. As of 2017, five patients are still alive and the mean overall survival has reached 48 months, which is a huge improvement when compared to the approximately 15 months expected with standard therapies.

CT scans of the brain of a patient that showed a complete disappearance of all brain and liver metastases (a) before and (b) 6 months aftercompleting the treatment

Ilixadencel, previously known as Intuvax, is composed ofactivated dendritic cellsderived from healthy donors that are injected into the tumor, where theyrecruit the patients own immune system. Its an off-the-shelf cell therapyobtained from healthy donors, which would result in easier manufacturing and lower costs as compared to patient-derived cells.

In theory, this strategy could be applied toany injectable solid tumor,whichis particularly exciting given that targetingsolid tumors is still a huge challenge. We believe that the future of cancer treatment lies in the rapidly evolving landscape of combination therapies and ilixadencel is uniquely positioned to become an integral part of modern combination regimens, saidAlex Karlsson-Parra, CSO of Immunicum, in a statement.

According to Carlos de Sousa, CEO of the company, the effort to publish the results is part of the companys strategy to communicate its data and build validation for its technology. As he commented during an oncology panel at Labiotech Refresh, the regulatory authorities in Europe are struggling to keep up with the rapid advances in the field.

Immunicum is not the only developing cell-based therapies for cancer. The French PDC*line Pharma is also focusing on dendritic cells, while many others compete to bring the promising CAR-T cell technology to the market.Ensuring the data is available is a great initiative to help build laws that will adequately regulate these novel technologies.

Images via xrender / Shutterstock;Laurell et al., Journal for ImmunoTherapy of Cancer 2017 5:52

Read the rest here:
Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer - Labiotech.eu (blog)

Making uses of the advances in cell therapy, Apollo Hospitals on Tuesday announced partnership with RMS REGROW, to offer new regenerative medicine cell therapy products that will be a boon for patients suffering from bone and cartilage damage.

The two products- Ossron and Chondron, will address unmet clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee.

In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India.

Through several clinical trials and evaluation studies that spanned around 8 years, the company has achieved the market authorization for the two cell therapy products.

Doctors will be trained in using the products by conducting live surgical workshops and conferences etc. both nationally and internationally.

Apollo Group wants to encourage research and innovation within India for the people of India. Our association with RMS Regrow is a step to inspire talent in India to further the advancement in developing innovative healthcare treatments to reduce the growing disease burden in India, said Dr Prathap C Reddy, founder-chairman, Apollo Hospitals.

Yash Sanghavi, founder and CEO- RMS REGROW, said, It has taken 8 years of dedicated effort and innovative research to develop the two revolutionary products that will change the modalities for bone and cartilage treatment in India.

Since last 70 years, only a handful of New Chemical Entities (NCE) have been developed in India, which demonstrates a dearth of innovator drugs and new medical technologies to address a large market of bone and joint disorders.

In India, more than 15 lakh orthopaedic procedures are performed each year and Regenerative Cell Therapy is a revolutionary treatment methodology which has immense potential to liberate consumers from Joint pain.

More here:
Apollo Hospitals bring innovative cell therapy to treat joint pain ... - Hindustan Times

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor (TCR) cell therapy. Catapult Therapy TCR developed the therapy as a treatment for blood cancers, but Cell Medica thinks it can retool it to take out solid tumors.

Production of the cell therapy entails modifying a patients own T cells to identify and destroy cells that express the WT1 protein, which is associated with mesothelioma and ovarian cancer. But early development of the WT1-TCR cell therapy has eschewed these solid tumors in favor of going after acute myeloid leukemia and myelodysplastic syndrome.

That is set to change under the ownership of Cell Medica. The British biotech plans to apply the Dominant TCR technology it licensed from UCL last year to the cell therapy to equip it to treat solid tumors. The technology is designed to increase the efficacy of engineered T cells by dialing up the expression of TCRs.

Our objective is to show how we can enhance any existing TCR cell therapy with the Dominant TCR technology to create a more effective treatment for patients with solid tumors who otherwise have a very poor prognosis, Cell Medica CEO Gregg Sando said in a statement.

Cell Medica plans to work on the therapy over the next year or so with a view to starting a phase 1/2 trial late in 2018. Catapult Therapy TCR has already tested the cell therapy in a small number of patients. But those studies looked at the unenhanced version of the candidate in blood cancers.

The earlier trials were sponsored by the Cell and Gene Therapy Catapult, which set up Catapult Therapy TCR in collaboration with UCL Business and Imperial Innovationsnow called Touchstone Innovationsin 2014. CGT Catapult committed 10 million to the subsidiary. Financial details of the takeover by Cell Medica werent disclosed.

CGT Catapult will remain involved in advancing the cell therapy. Cell Medica is setting up a cell therapy manufacturing operation at CGT Catapults site in Stevenage. That operation will produce the WT1-TCR cell therapy and potentially other candidates. Cell Medica plans to transfer the WT1-TCR cell therapy to the site over the next 12 months while working with CGT Catapult to develop a commercial-scale production process.

The agreement continues a busy period for Cell Medica. Over the past 12 months the biotech has built out its technology base through the UCL licensing pact, agreements with Baylor College of Medicine and the acquisition of Delenex Therapeutics. Cell Medica followed up on these deals by raising 60 million to expand its clinical-phase pipeline.

See original here:
Cell Medica buys clinical-phase WT1-TCR cell therapy - FierceBiotech

Partnership will help hospital chain offer innovative orthopaedic treatment

New Delhi, June 19:

Patients suffering from orthopaedic problems such as arthritis may now have a better and painless option than replacement surgeries.

The countrys largest hospital chain, Apollo Hospitals, on Monday entered into a tie-up with a Pune-based up-and-coming regenerative medicine company RMS Regrow to offer cell therapy treatment for bone and cartilage problems.

This exclusive partnership with RMS Regrow will allow the Chennai-headquartered hospital chain to offer advanced cell therapy treatment to patients suffering from a variety of bone or cartilage related problems caused by sports injury, accidents, ageing or wear and tear. In India, more than 1.5 million orthopaedic procedures are performed every year.

The techniques developed by RMS Regrow Ossron for bone and Chondron for cartilage are among the first set of cell therapy-based treatment modalities to receive regulatory approvals in India, said Satyen Sanghavi, Chief Scientific Officer, RMS, at a press conference here.

Cell therapy is a technique in which healthy cellular material is injected into a patient to replace diseased or dysfunctional cells.

In orthopaedic problems, it has the potential to be an alternative to knee and hip replacements.

According to Prathap Reddy, Chairman, Apollo Hospitals, the treatment will be available in 40 Apollo hospitals at a cost of 3-4 lakh, which is a fraction of the cost that one needs for similar treatment in advanced countries.

Trials carried out

Across its hospitals, as many as 200 orthopaedics have been trained to carry out the procedures which involve harvesting healthy bone or cartilage tissues from the patient and growing them outside the body before transplanted back into the affected body part.

The techniques have been found to be not only safe but very effective, Sanghavi said. While Chondron clinical trials were carried out in 350 patients, the Ossron modality was tested in 150 patients suffering from bone related problems.

Most of these trials were done in partnership with Apollo, he said.

The techniques were found to be more effective in people the age of 65 years.

According to Sanghavi, RMS Regrow developed these techniques at an R&D cost of 45 crore and over a period of eight years.

(This article was published on June 19, 2017)

Please enter your email. Thank You.

Newsletter has been successfully subscribed.

Go here to read the rest:
Apollo Hospitals ties up with cell therapy firm - Hindu Business Line

Photo Credit: Nati Shohat / Flash 90

Patients with severe and end-stage heart failure have few treatment options available to them apart from transplants and miraculous stem cell therapy. But a new Tel Aviv University study has found that stem cell therapy may in fact harm patients with heart disease.

The research, led by Prof. Jonathan Leor of TAUs Sackler Faculty of Medicine and Sheba Medical Center and conducted by TAUs Dr. Nili Naftali-Shani, explores the current practice of using cells from the host patient to repair tissue and contends that this can prove deleterious or toxic for patients. The study was recently published in the journal Circulation.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, said Prof. Leor. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

Tissue or adult stem cells blank cells that can act as a repair kit for the body by replacing damaged tissue encourage the regeneration of blood vessel cells and new heart muscle tissue. Faced with a worse survival rate than many cancers, a number of patients with heart failure have turned to stem cell therapy as a last resort.

But our findings suggest that stem cells, like any drug, can have adverse effects, said Prof. Leor. We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient.

Hope for improved cardiac stem cell therapy

In addition, the researchers also discovered the molecular pathway involved in the negative interaction between stem cells and the immune system as they isolated stem cells in mouse models of heart disease. After exploring the molecular pathway in mice, the researchers focused on cardiac stem cells in patients with heart disease.

The results could help improve the use of autologous stem cells those drawn from the patients themselves in cardiac therapy, Prof. Leor said.

We showed that the deletion of the gene responsible for this pathway can restore the original therapeutic function of the cells, said Prof. Leor. Our findings determine the potential negative effects of inflammation on stem cell function as theyre currently used. The use of autologous stem cells from patients with heart disease should be modified. Only stem cells from healthy donors or genetically engineered cells should be used in treating cardiac conditions.

The researchers are currently testing a gene editing technique (CRISPER) to inhibit the gene responsible for the negative inflammatory properties of the cardiac stem cells of heart disease patients. We hope our engineered stem cells will be resistant to the negative effects of the immune system, said Prof. Leor.

Meanwhile, for those unable to profit from stem cell therapy, researchers at Ben Gurion University of the Negev (BGU) have developed a revolutionary new drug that may reverse the damage and repair the diseased heart.

The newly developed drug is a polymer which reduces the inflammation in cardiovascular tissue and stops plaque build-up in arteries. Then it goes one step further and removes existing plaque in the heart, leaving healthy tissue behind.

Professor Ayelet David, a researcher at BGU revealed the drug might also help people suffering from diabetes, hypertension and other conditions associated with old age.

Read the original:
Israeli Scientists: Stem Cell Therapy Not Good for All Heart Patients - The Jewish Press - JewishPress.com

TV documentary on pain treatment funded by doctor with

TV documentary on pain treatment funded by doctor with industry ties

For some chronic pain patients, without opioids, life would

For some chronic pain patients, without opioids, life would be torture

Googles bold bid to transform medicine hits turbulence under

Googles bold bid to transform medicine hits turbulence under a divisive CEO

At first meeting of Trumps opioid commission, health advocates

At first meeting of Trumps opioid commission, health advocates plead for Medicaid spending

This bill would reinstate a controversial drug discount for

This bill would reinstate a controversial drug discount for some hospitals

Up and down the ladder: The latest comings and

Up and down the ladder: The latest comings and goings

See original here:
On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics - STAT

June 15, 2017 Researchers from the A*STAR Bioprocessing Technology Institute involved in the study. Credit: A*STAR Bioprocessing Technology Institute

Stem cells have paved the way for a new era in regenerative medicine, but their use is fraught with risk. Now, A*STAR scientists have developed an antibody that could make stem cell therapy safer.

Human pluripotent stem cells that can differentiate in a petri dish to become any cell needed to repair tissues and organs, hold great promise. Since the first human embryonic stem cells were isolated in 1998, scientists have edged closer to developing 'cell therapy' for humans. In early 2017, a Japanese man became the first patient to receive a retina transplant made of reprogrammed pluripotent stem cells to treat macular degeneration.

These potential rewards come with great risk. Differentiating stem cells into other cell types is an imperfect process, and any stem cells that remain in a culture of transplanted cells can form dangerous by-products, including tumors, such as teratomas.

"If stem cells become a cell therapy product there will be the question of safety," Andre Choo, from the A*STAR Bioprocessing Technology Institute, explains.

Choo and his team are working to make stem cell treatments safer by creating antibodies that 'clean up' the pluripotent stem cells which fail to differentiate.

In 2016, the researchers used a whole-cell immunization strategy to generate different antibodies by injecting mice with viable embryonic stem cells. They then isolated the antibodies and tested their ability to search and destroy pluripotent stem cells in a culture dish.

One antibody, tagged 'A1', was discovered which destroyed pluripotent stem cells in minutes but left other cells unharmed.

Choo's team then focused on how the antibody destroyed its target. The scientists discovered that A1 docks to sugar molecules that are only present on the surface of embryonic stem cells, setting off a signaling cascade that ruptures the stem cell.

"That was quite exciting because it now gives us a view of the mechanism that is responsible for the cell-killing effect," says Choo.

Understanding this mechanism could allow Choo's team to combine the A1 antibody with other treatments to clean stem cells from a mixture of differentiated cells even more effectively.

The finding could also pinpoint how best to target antibodies against sugar molecules on other unwanted cells, including cancer cells.

"We hope that in the near future regenerative medicine will have a place in the clinic," says Choo, who wants this antibody to be part of that process.

The A*STAR-affiliated researchers contributing to this research are from the Bioprocessing Technology Institute. For more information about the team's research, please visit the Stem Cell 1 group webpage.

Explore further: New tools to study the origin of embryonic stem cells

More information: Ji Yun Zheng et al. Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis, Cell Death and Differentiation (2017). DOI: 10.1038/cdd.2016.164

Researchers at Karolinska Institutet have identified cell surface markers specific for the very earliest stem cells in the human embryo. These cells are thought to possess great potential for replacing damaged tissue but ...

An International Reserach Team coordinated by Igb-Cnr has discovered a key role of vitamins and amino acids in pluripotent stem cells. The research is published in Stem Cell Reports, and may provide new insights in cancer ...

A*STAR researchers and colleagues have developed a method to isolate and expand human heart stem cells, also known as cardiac progenitor cells, which could have great potential for repairing injured heart tissue.

Adding just the right mixture of signaling moleculesproteins involved in developmentto human stem cells can coax them to resemble somites, which are groups of cells that give rise to skeletal muscles, bones, and cartilage ...

Scientists have discovered the gene essential for chemically reprogramming human amniotic stem cells into a more versatile state similar to embryonic stem cells, in research led by UCL and Heinrich Heine University.

Oxygen in the air is well known to cause damaging rust on cars through a process known as oxidation. Similarly, a research group at Lund University in Sweden, has now identified that certain cells during embryonic development ...

Scientists have developed a new technique for investigating the effects of gene deletion at later stages in the life cycle of a parasite that causes malaria in rodents, according to a new study in PLOS Pathogens. The novel ...

The drill holes left in fossil shells by hunters such as snails and slugs show marine predators have grown steadily bigger and more powerful over time but stuck to picking off small prey, rather than using their added heft ...

Scientists from Rutgers University-New Brunswick, the biotechnology company NAICONS Srl., and elsewhere have discovered a new antibiotic effective against drug-resistant bacteria: pseudouridimycin. The new antibiotic is produced ...

Almost all life on Earth is based on DNA being copied, or replicated. Now for the first time scientists have been able to watch the replication of a single DNA molecule, with some surprising findings. For one thing, there's ...

Researchers have identified properties in DNA's protective structure that could transform the way scientists think about the human genome.

Until now, the fauna of the Himalayas was considered to be an "immigration fauna", with species that have immigrated primarily from neighbouring regions to the west and east since the geological formation of this mountain ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original:
Lab-created antibody could hold the secret to making stem cell ... - Phys.Org

AUSTIN, Texas -- The legal battle to get patients access to stem cell therapy in Texas is closer to reality.

Gov. Greg Abbott signed such legislation into law this week, and itmeans some patients will be heading into uncharted medical territory.

Come Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.

MORE |Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments

Currently, mostpatients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.

"This is going to protect patient health, and provide for the treatments to be done here locally at home," saidMike Byrom, the Chief Science Officer at Austin stem cell bankBioEden.

Byrom said the new lawwill keep patients in the country, and will provide renewed hope for those with serious ailments.

This hope resulted in anemotional fight this session.

Texas State Rep. Drew Springer, R-Gainesville, gave an impassioned speech for the legislation as the deadline to read new bills approached, urging lawmakers to keep it from dying.

"I'll be damned if we don't get the chance tonight to hear the very next bill that opens up the doors of medical science," saidSpringer, whose wife is wheelchair-bound."It might give somebody like my wife a chance to walk."

But not everyone's convinced this is the right way to go.

"We want access for patients to the best drugs, but we think they ought to go through the FDA approval process," saidTexans for Cures Chairman David Bales.

Bales was one of the few people who testified against the bill. While he supports more stem cell research,hearguesthe state should fund it, rather than letting for-profit businesses lead the way.

"You run the risk of medical fraud because a lot of these guys, a lot of these patients, are paying a lot of money, to physicians and drug manufacturers who haven't gone through the right process,"Balessaid.

Patients who will be participating in stem cell therapy procedures will give up their right to take legal action if something goes wrong.

---

Join the Discussion:

Follow Capital Tonight Texas on Facebook & Twitter

Keep the conversation going on our political blog: Capital Roundup .

More here:
New Law Opens Door for Stem Cell Therapy in Texas - Spectrum News

Sessions/Tracks

Track 1:Molecular Biology

Molecular biologyis the study of molecular underpinnings of the processes ofreplication,transcription,translation, and cell function. Molecular biology concerns themolecularbasis ofbiologicalactivity between thebiomoleculesin various systems of acell,gene sequencingand this includes the interactions between theDNA,RNAand proteinsand theirbiosynthesis. Inmolecular biologythe researchers use specific techniques native to molecular biology, increasingly combine these techniques and ideas from thegeneticsandbiochemistry.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

2nd World Congress onHuman Genetics&Genetic Disorders, November 02-03, 2017 Toronto, Canada; 9th International Conference onGenomicsandPharmacogenomics, June 15-16, 2017 London, Uk; 6th International Conference and Exhibition onCellandGene Therapy, Mar 27-28, 2017 Madrid, Spain; Gordon Research Conference,Viruses&Cells, 14 - 19 May 2017, Lucca, Italy;Human Genome Meeting(HGM 2017), February 5-7 2017, Barcelona, Spain; Embl Conference:Mammalian GeneticsAndGenomics:From Molecular Mechanisms To Translational Applications, Heidelberg, Germany, October 24, 2017;GeneticandPhysiological Impacts of Transposable Elements, October 10, 2017, Heidelberg, Germany.

American Society for Cell Biology;The Society for Molecular Biology & Evolution;American Society for Biochemistry and Molecular Biology;The Nigerian Society of Biochemistry and Molecular Biology;Molecular Biology Association Search Form - CGAP.

Track 2:Gene Therapy and Genetic Engineering

Thegenetic engineeringis also called asgenetic modification. It is the direct manipulation of an organism'sofgenomeby usingbiotechnology. It is a set of technologies used to change the genetic makeup of the cell and including the transfer of genes across species boundaries to produce improved novelorganisms. Genesmay be removed, or "knocked out", using anuclease.Gene is targetinga different technique that useshomologousrecombinationto change anendogenous gene, and this can be used to delete a gene, removeexons, add a gene, or to introducegenetic mutations. There is an dna replacement therapy, Genetic engineering does not normally include traditional animal and plant breeding, gene sequencing, in vitro fertilization, induction of polyploidy,mutagenesisand cell fusion techniques that do not use recombinant nucleic acids or a genetically modified organism in the process,diseases treated with gene therapywas initially meant to introduce genes straight into human cells, focusing on diseases caused by single-gene defects, such as cystic fibrosis, hemophilia, muscular dystrophy and sickle cell anemia

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

8thWorld Congress onMolecular Pathology, June 26-27, 2017 San Diego, USA; 11thInternational Conference onSurgical Pathology& Practice, March 27-28, 2017, MADRID, SPAIN; 13th EuropeanPathologyCongress, Aug 02-03, 2017, MILAN, ITALY; 28th Annual Meeting, Austrian Society ForHuman GeneticsAnd The Swiss Society OfMedical GeneticsCombined Meeting 2017 march 29, 2017 - March 31, 2017, bochum , Germany.

Association for Clinical Genetic Science;Genetics Society of America | GSA;Association of Genetic Technologists;Molecular Genetics - Human Genetics Society of Australasia;Genetic Engineering - Ecological Farming Association.

Track 3:Cell & Gene Therapy

Cell therapy is also calledcellular therapyorCyto therapy, in which cellular material is injected into patient this generally means intact, living cells. The first category iscell therapyin mainstream medicine. This is the subject of intense research and the basis of potential therapeutic benefit. Such research can be controversial when it involves human embryonic material. The second category is in alternative medicine, and perpetuates the practice of injecting animal materials in an attempt to cure disease.Gene therapyis the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy is a way to fix agenetic problemat its source. The polymers are either translated into proteins, interfere with targetgene expression, or possibly correct genetic mutations. The most common form uses DNA that encodes a functional,therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a "vector", which carries the molecule inside cells. Vectors used in gene therapy, the vector incorporates genes intochromosomes. The expressed nucleases then knock out and replace genes in the chromosome. The Center forCell and Gene Therapyconducts research into numerous diseases, including but not limited to PediatricCancer, HIV gliomaandCardiovascular disease.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

2nd World Congress onHuman Genetics&Genetic Disorders, November 02-03, 2017 Toronto, 27 Canada ; 7th International Conference onPlant Genomics, July 03-05, 2017, Bangkok, Thailand ; American Society ofGeneandCell Therapy(ASGCT) 20th Annual Meeting, 10 - 13 May 2017, Washington, DC;Genomic Medicine for Clinicians(course), January 25-27, 2017, Hinxton , Cambridge, UK; Embo Conference:ChromatinandEpigenetics, Heidelberg, Germany, May 3, 2017; 14th International Symposium on Variants in theGenomeSantiago de Compostela, Galicia, Spain, June 5 - 8, 2017;

Genetics and Molecular Medicine - American Medical Association;Genetics Society of America / Gsa;British Society for Genetic Medicine;British Society for Gene and Cell Therapy; Australasian Gene Therapy Society.

Track 4:Cell Cancer Immunotherapy

Immunologydeals with the biological and biochemical basis for the body's defense against germs such as bacteria, virus and mycosis (fungal infections) as well as foreign agents such asbiological toxinsand environmental pollutants, and failures and malfunctions of these defense mechanisms. Cancer immunotherapy is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. The immune system normally uses them to fight pathogens. A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases. Some types of immunotherapy only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG), and some monoclonal antibodies.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

9thAnnual Meeting onImmunologyandImmunologist, July 03-05, 2017 Kuala Lumpur, Malaysia; 8th MolecularImmunology&ImmunogeneticsCongress, March 20-21, 2017 Rome, Italy; 8th EuropeanImmunologyConference, June 29-July 01, 2017 Madrid, Spain; July 03-05, 2017; B Cells and T Follicular Helper Cells Controlling Long-Lived Immunity (D2), April 2017, 2327, Whistler, British Columbia, Canada; Mononuclear Phagocytes in Health,Immune Defense and Disease, 304 May, Austin, Texas, USA;Modeling Viral Infections and ImmunityMAY 2017, 14, Estes Park, Colorado, USA; IntegratingMetabolism and Immunity(E4)292 June, Dublin, Ireland.

The American Association of Immunologists;Clinical Immunology Society ; Indian Immunology Society;IUIS - International Union of Immunological Societies;American Society for Histocompatibility and Immunogenetics.

Track 5:Clinical Genetics

Clinical geneticsis the practice of clinical medicine with particular attention tothe hereditary disorders. Referrals are made togenetics clinicsfor the variety of reasons, includingbirth defects,developmental delay,autism,epilepsy, and many others. In the United States, physicians who practice clinical genetics are accredited by theAmerican Board of Medical Genetics and Genomics(ABMGG).In order to become a board-certified practitioner of a Clinical Genetics, a physician must complete minimum of 24 months of his training in a program accredited by the ABMGG. Individual seeking acceptance intoclinical geneticstraining programs and should hold an M.D. or D.O. degree (or their equivalent)and he/she have completed a minimum of 24 months of their training in ACGME-accredited residency program internal medicine, pediatrics and gynecology or other medical specialty.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

Belgian Society OfHuman GeneticsMeeting 2017 february 17, 2017, Belgium; American College Of Medical Genetics 2017 AnnualClinical GeneticsMeeting march 21-25 2017, phoenix , United States; German Society Of Human Genetics 28th Annual Meeting, Austrian Society ForHuman GeneticsAnd The Swiss Society OfMedical GeneticsCombined Meeting 2017 march 29, 2017 - March 31, 2017, bochum , Germany; Spanish Society OfHuman GeneticsCongress 2017april 25, 2017 - April 28, 2017 madrid , Spain;

Clinical Genetics Associates;Clinical Genetics Society(CGS);The genetic associate;International Conference on Clinical and Medical Genetics;Association for Clinical Genetic Science;The American Society of Human Genetics.

Track 6:Pharmacogenetics

Pharmacogeneticsis the study of inherited genetic differences in drug metabolic pathways which can affect individual responses towards the drugs, both in their terms of therapeutic effect as well as adverse effects. In oncology, Pharmacogenetics historically is the study ofgerm line mutations(e.g., single-nucleotide polymorphisms affecting genes coding forliver enzymesresponsible for drug deposition and pharmacokinetics), whereaspharmacogenomicsrefers tosomatic mutationsin tumoral DNA leading to alteration in drug response.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

Spanish Society OfHuman GeneticsCongress 2017april 25, 2017 - April 28, 2017, madrid , Spain; 8th World Congress onPharmacology, August 07-09, 2017 Paris, France; World Congress onBio therapeutics, May 22-23, 2017, Mexico City, Mexico; 8th World Congress OnPharmacologyAndToxicology, July 24-26, 2017, Melbourne, Australia; German Society Of Human Genetics 28th Annual Meeting, Austrian Society ForHuman GeneticsAnd The Swiss Society OfMedical GeneticsCombined Meeting 2017march 29, 2017 - March 31, 2017 bochum , Germany.

Pharmacogenomics - American Medical Association;Associate Principal Scientist Clinical Pharmacogenetics;European Society of Pharmacogenomics and Personalised Therapy;Genome-wide association studies in pharmacogenomics.

Track 7:Molecular Genetic Pathology

Molecular genetic pathologyis an emerging discipline withinthe pathologywhich is focused in the study and diagnosis of disease through examination of molecules within the organs, tissues or body fluids. A key consideration is more accurate diagnosis is possible when the diagnosis is based on both morphologic changes in tissuestraditional anatomic pathologyand onmolecular testing. Molecular Genetic Pathology is commonly used in diagnosis of cancer and infectious diseases. Integration of "molecular pathology" and "epidemiology" led tointerdisciplinaryfield, termed "molecular pathological epidemiology" (MPE),which representsintegrative molecular biologicand population health science.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

8th World Congress OnMolecular Pathology, June 26-27, 2017 San Diego, USA; 11th International Conference OnSurgical Pathology& Practice, March 27-28, 2017, Madrid, Spain; 13th EuropeanPathologyCongress, Aug 02-03, 2017, Milan, Italy; Embl Conference:Mammalian GeneticsAndGenomics, Heidelberg, Germany, October 24, 2017; Embo|Embl Symposium: TheMobile Genome: Genetic And Physiological Impacts Of Transposable Elements, Heidelberg, Germany, October 10, 2017.

Clinical Pathology Associates Molecular Pathology; Association mapping Wikipedia;Association for Molecular Pathology(AMP);Molecular Pathology - Association of Clinical Pathologists;SELECTBIO - Molecular Pathology Association of India.

Track 8:Gene Mapping

Genomemappingis to place a collection of molecular markers onto their respective positions ongenome.Molecular markerscome in all forms. Genes can be viewed as one special type of genetic markers in construction ofgenome maps, and the map is mapped the same way as any other markers. The quality ofgenetic mapsis largely dependent upon the two factors, the number of genetic markers on the map and the size of themapping population. The two factors are interlinked, and as larger mapping population could increase the "resolution" of the maps and prevent the map being "saturated". Researchers begin a genetic map by collecting samples of blood or tissue from family members that carry a prominent disease or trait and family members that don't. Scientists then isolate DNA from the samples and closely examine it, looking for unique patterns in the DNA of the family members who do carry the disease that the DNA of those who don't carry the disease don't have. These unique molecular patterns in the DNA are referred to as polymorphisms, or markers.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

3rd WorldBio Summit&Expo, Abu Dhabi, UAE, June 19-21, 2017; 9th International Conference onGenomicsandPharmacogenomicsJune 15-16, 2017 London, Uk; Keystone Symposium: Mononuclear Phagocytes in Health,Immune DefenseandDisease, 304 May 2017, Austin, Texas, USA;Molecular Neurodegeneration(course) Hinxton, Cambridge, UK, January 9-14, 2017;

Association for Clinical Genetic Science;Genome-wide association study Wikipedia;Gene mapping by linkage and association analysis NCBI;Gene mapping by linkage and association analysis | Springer Link.

Track 9:ComputationalGenomics

Computational genomics refers to the use of computational and statistical analysis to decipherbiologyfromgenome sequencesand related data, including DNA and RNA sequence as well as other "post-genomic" data. This computational genomics is also known asComputational Genetics. These, in combination with computational and statistical approaches to understanding the function of the genes and statistical association analysis, this field is also often referred to as Computational and Statistical Genetics/genomics. As such, computational genomics may be regarded as a subset of bioinformatics and computational biology, but with a focus on using whole genomes rather than individual genes to understand the principles of how the DNA of a species controls its biology at the molecular level and beyond. With the current abundance of massive biological datasets, computational studies have become one of the most important means to biological discovery.The field is defined and includes foundations in thecomputer sciences,applied mathematics, animation, biochemistry, chemistry, biophysics,molecular genetics,neuroscienceandvisualization. Computational biology is different from biological computation, which is a subfield of computer engineering using bioengineering and biology to build computers, but is similar tobioinformatics.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

Modeling Viral Infections and Immunity,10. MAY 2017, 14, Estes Park, Colorado, USA;Integrating Metabolism and Immunity(E4)292 June, Dublin, Ireland; EMBL Conference:Mammalian GeneticsandGenomics, Heidelberg, Germany, October 24, 2017; EMBO|EMBL Symposium: The Mobile Genome:GeneticandPhysiological Impacts of Transposable Elements, Heidelberg, Germany, October 10, 2017;

American Association of Bio analysts - Molecular/Genetic Testing;ISCB - International Society for Computational Biology;International Society for Computational Biology Wikipedia;Bioinformatics societies OMICtools;Towards an Australian Bioinformatics Society.

Track 10:Molecular Biotechnology

Molecular Biotechnologyis the use of living systems and organisms to develop or to make products, or "any technological application that uses the biological systems, living organisms or derivatives, to make or modify products or processes for specific use. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product. The completion of the human genome project has opened a myriad of opportunities to create new medicines and treatments, as well as approaches to improve existing medicines. Molecular biotechnology is a rapidly changing and dynamic field. As the pace of advances accelerates, its influence will increase. The importance and impact of molecular biotechnology is being felt across the nation. Depending on the tools and applications, it often overlaps with the related fields of bioengineering,biomedical engineering, bio manufacturing andmolecular engineering.Biotechnologyalso writes on the pure biological sciences animalcell culture, biochemistry,cell biology, embryology, genetics, microbiology, andmolecular biology.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

8th EuropeanImmunologyConference, June 29-July 01, 2017 Madrid, Spain; World Congress onBio therapeutics, May 22-23, 2017, Mexico City, Mexico;Human Genome Meeting(HGM 2017), February 5-7 2017, Barcelona, Spain;Integrating MetabolismandImmunity (E4), 292 June, Dublin, Ireland.

Biotech Associations - Stanford University;Indian Society of Genetics, Biotechnology Research & Development;Genetics and Molecular Medicine - American Medical Association;Genetics Society of America | GSA, British Society for Genetic Medicine;Heritability in the Era of Molecular Genetics - Association for Psychological science.

Track 11:Genetic Transformation

Genetic Transformationis the genetic alteration of cell resulting from the direct uptake and incorporation ofexogenous genetic materialfrom its surroundings through thecell membrane. Transformation is one of three processes for horizontal gene transfer, in which exogenous genetic material passes from bacterium to another, the other two being conjugation transfer of genetic material between two bacterial cells in direct contact andTransductioninjection offoreign DNAby a bacteriophage virus into thehost bacterium. And about 80 species of bacteria were known to be capable of transformation, in 2014, about evenly divided betweenGram-positiveandGram-negative Transformation" may also be used to describe the insertion of new genetic material into non-bacterial cells, including animal and plant cells.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

13th EuropeanPathologyCongress, Milan, Italy; Embl Conference:Mammalian GeneticsAndGenomics, Heidelberg, Germany, October 24, 2017; Embo|Embl Symposium: TheMobile Genome: Genetic And Physiological Impacts Of Transposable Elements, Heidelberg, Germany, October 10, 2017; 2nd World Congress onHuman Genetics&Genetic Disorders, November 02-03, 2017 Toronto, Canada; 9th International Conference onGenomicsandPharmacogenomics, June 15-16, 2017 London, Uk;

American Society of Gene & Cell Therapy: ASGCT;Gene Therapy Societies and Patient Organizations - Gene Therapy Net;European Society of Gene and Cell Therapy (ESGCT);British Society for Gene and Cell Therapy;Gene Therapy - American Medical Association.

Track 12:Genetic Screening

Genetic screenis an experimental technique used to identify and select the individuals who possess a phenotype of interest inmutagenized population. A genetic screen is a type ofphenotypic screen. Genetic screen can provide important information on gene function as well as the molecular events that underlie a biological process or pathway. While thegenome projectshave identified an extensive inventory of genes in many different organisms, genetic screens can provide valuable insight as to how thosegenes function.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

13th EuropeanPathologyCongress, Aug 02-03, 2017, Milan, Italy; 2nd World Congress onHuman Genetics&Genetic Disorders, November 02-03, 2017 Toronto, 27 Canada; 7th International Conference onPlant Genomics, July 03-05, 2017, Bangkok, Thailand; Embl Conference:Mammalian GeneticsAndGenomics, Heidelberg, Germany, October 24, 2017; Embo|Embl Symposium: TheMobile Genome: Genetic And Physiological Impacts Of Transposable Elements, Heidelberg, Germany, October 10, 2017, 10 - 13 May 2017, American Society ofGeneandCell Therapy(ASGCT) 20th Annual Meeting, Washington, DC;

Association for Clinical Genetic Science; Association for Molecular Pathology (AMP);Mapping heritability and molecular genetic associations with cortical;Genetics and Molecular Medicine - American Medical Association.

Track 13:Regulation of Gene Expression

Regulation of Gene expressionincludes a wide range of mechanisms that are used by cells to increase or decrease the production of specific gene products (protein or RNA), and is informally termed gene regulation. Sophisticated programs of gene expression are widely observed in biology, Virtually any step of gene expression can be modulated, fromtranscriptional initiation,RNA processing, and post-translational modificationof a protein. Often, one gene regulator controls another in a gene regulatory network. Any step of gene expression may be modulated, from theDNA-RNA transcriptionstep to post-translational modification of a protein.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

7th International Conference onPlant Genomics, July 03-05, 2017, Bangkok, Thailand; EMBO|EMBL Symposium: The Mobile Genome:GeneticandPhysiological Impacts of Transposable Elements, Heidelberg, Germany, October 10, 2017; 10. MAY 2017, 14, Estes Park, Colorado, USA,Modeling Viral Infections and Immunity; 292 June, Dublin, Ireland,Integrating Metabolism and Immunity(E4); MAY 2017, 14, Estes Park, Colorado, USA,Modeling Viral InfectionsandImmunity; 8th EuropeanImmunologyConference, June 29-July 01, 2017 Madrid, Spain; 9th International Conference onGenomicsandPharmacogenomics, June 15-16, 2017 London, Uk;

Gene Therapy Societies and Patient Organizations - Gene Therapy Net;European Society of Gene and Cell Therapy (ESGCT);British Society for Gene and Cell Therapy;Gene Therapy - American Medical Association

Track 14: Cancer Gene Therapy

Cancer is an abnormal growth of cells the proximate cause of which is an imbalance in cell proliferation and death breaking-through the normal physiological checks and balances system and the ultimate cause of which are one or more of a variety of gene alterations. These alterations can be structural, e.g., mutations, insertions, deletions, amplifications, fusions and translocations, or functional (heritable changes without changes in nucleotide sequence). No single genomic change is found in all cancers and multiple changes (heterogeneity) are commonly found in each cancer generally independent of histology. In healthy adults, the immune system may recognize and kill the cancer cells or allow non-detrimental host-cancer equilibrium; unfortunately, cancer cells can sometimes escape the immune system resulting in expansion and spread of these cancer cells leading to serious life threatening disease. Approaches to cancer gene therapy include three main strategies: the insertion of a normal gene into cancer cells to replace a mutated (or otherwise altered) gene, genetic modification to silence a mutated gene, and genetic approaches to directly kill the cancer cells. Pathway C represents immunotherapy using altered immune cells. Another unique immunotherapy strategy facilitated by gene therapy is to directly alter the patient's immune system in order to sensitize it to the cancer cells. One approach uses mononuclear circulating blood cells or bone marrow gathered from the patient.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

8th EuropeanImmunologyConference, June 29-July 01, 2017 Madrid, Spain; World Congress onBio therapeutics, May 22-23, 2017, Mexico City, Mexico;Human Genome Meeting(HGM 2017), February 5-7 2017, Barcelona, Spain;Integrating MetabolismandImmunity (E4), 292 June, Dublin, Ireland.

Biotech Associations - Stanford University;Indian Society of Genetics, Biotechnology Research & Development;Genetics and Molecular Medicine - American Medical Association;Genetics Society of America | GSA, British Society for Genetic Medicine;Heritability in the Era of Molecular Genetics - Association for Psychological science.

Track 15:Genetic Transplantation

Transplantation genetics is the field of biology and medicine relating to the genes that govern the acceptance or rejection of a transplant. The most important genes deciding the fate of a transplanted cell, tissue, or organ belong to what is termed the MHC (the major histocompatibility complex). Genetic Transplantation is the moving of an organ from one body to another or from a donor site to another location on the person's own body, to replace the recipient's damaged or absent organ. Organs and/or tissues that aretransplantedwithin the same person's body are calledauto grafts. Transplants that are recently performed between two subjects of the same species are calledallografts. Allografts can either be from a living or cadaveric source Organs that can be transplanted are the heart, kidneys, liver, lungs, pancreas, intestine, and thymus. The kidneys are the most commonlytransplanted organs, followed by the liver and then the heart. The main function of the MHC antigens is peptide presentation to the immune system to help distinguish self from non-self. These antigens are called HLA (human leukocyte antigens). They consists of three regions: class I (HLA-A,B,Cw), class II (HLA-DR,DQ,DP) and class III (no HLA genes)

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

8th World Congress onPharmacology, August 07-09, 2017 Paris, France; International Conference onClinicalandMolecular Genetics, Las Vegas, USA, April 24-26, 2017; Aug 02-03, 2017, 13th EuropeanPathologyCongress, Milan, Italy; Embl Conference:Mammalian GeneticsAndGenomics, Heidelberg, Germany, October 24, 2017; 7th International Conference onPlant Genomics, July 03-05, 2017, Bangkok, Thailand.

American society of Transplantation;American Society of Transplant Surgeons: ASTS; Patient associations. Donation and transplantation;American Society of Gene & Cell Therapy ASGCT;Gene Therapy Societies and Patient Organizations - Gene Therapy Net.

Track 16:Cytogenetics

Cytogeneticsis a branch ofgeneticsthat is concerned withstudy of the structure and function of the cell, especially thechromosomes. It includes routine analysis of G-banded chromosomes, othercytogenetic banding techniques, as well as molecular Cytogenetics such as fluorescent in suitable hybridization FISH and comparativegenomic hybridization.

RelatedMolecular Biology Conferences| Genetics Conferences|Gene Therapy Conferences|Biotechnology Conferences| Immune Cell Therapy Conferences

9thAnnual Meeting onImmunologyandImmunologist, July 03-05, 2017 Kuala Lumpur, Malaysia; 8th MolecularImmunology&ImmunogeneticsCongress, March 20-21, 2017 Rome, Italy; 8th EuropeanImmunologyConference, June 29-July 01, 2017 Madrid, Spain; July 03-05, 2017; B Cells and T Follicular Helper Cells Controlling Long-Lived Immunity (D2), April 2017, 2327, Whistler, British Columbia, Canada.

European Cytogeneticists Association;Association of Genetic Technologists;Association for Clinical Genetic Science;Cytogenetics - Human Genetics Society of Australasia;European Cytogeneticists Association

Molecular Biology 2016

Molecular Biology 2016 Report

2ndWorld Bio Summit & Molecular Biology Expowas organized during October 10-12, 2016 at Dubai, UAE. The conference was marked with the attendance ofEditorial Board Members of supporting journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference fruitful and productive.

This conference was based on the theme Recent advances in Bio Science which included the following scientific tracks:

Molecular Biology

Microbiology

Analytical Molecular Biology

Bioinformatics

Biochemistry and Molecular Biology

Molecular Biology and Biotechnology

Cancer Molecular Biology

Computational Biology

Molecular Biology of the Cell

Molecular biology of the cardiovascular system

Molecular Biology in Cellular Pathology

Molecular Biology of Diabetes

Molecular Biology and Genetic Engineering

Enzymology and Molecular Biology

Molecular Biology of the Gene

Continued here:
Molecular Genetics - Cell and Gene Therapy Conferences

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ... The Scientist Cambridge, UK, 14 June 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the Company), the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and ... and more »

More:
Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ... - The Scientist